Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Markers in Multiple Sclerosis

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Multiple sclerosis (MS) is chronic autoimmune disease with a high level of heterogeneity in its course and prognosis. More than half of patients with MS do not discuss their long-term prognosis with the treating doctor. Most patients regard personalized information on the course of MS as extremely important in relation to taking decisions on family planning, choice of profession, and treatment. Determination of prognosis in routine clinical practice uses clinical markers, though these are nominally divided into favorable and unfavorable factors, which allows general conclusions regarding the prognosis of MS to be made. Neuroimaging and biological markers are mainly used for research purposes, though they are now actively employed in clinical studies to assess the effects of treatment on the organic causes of persistent disability. This review describes studies of the prognostic value of various clinical, neuroimaging, and biological markers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. All-Russian Society of Neurologists, Clinical Guidelines for Multiple Sclerosis (2019), https://www.ructrims.org/files/%D0%9A%D0%BB%D0%B8%D0%BD%20%D1%80%D0%B5%D0%BA%D0%A0%D0%A1_2019_3.docx, acc. Feb. 15, 2021.

  2. N. Ghasemi, S. Razavi, and E. Nikzad, “Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy,” Cell J., 19, No. 1, 1–10 (2017), https://doi.org/10.22074/cellj.2016.4867.

  3. Q. Wu, E. A. Mills, Q. Wang, et al., “Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis,” JCI Insight, 5, No. 3 (2020), https://doi.org/10.1172/jci.insight.134251.

  4. T. Ziemssen, K. Akgün, and W. Brück, “Molecular biomarkers in multiple sclerosis,” J. Neuroinflamm., 16, No. 1, 272 (2019), https://doi.org/10.1186/s12974-019-1674-2.

    Article  Google Scholar 

  5. R. Bergamaschi, C. Berzuini, A. Romani, and V. Cosi, “Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis,” J. Neurol. Sci., 189, No. 1–2, 13–21 (2001), https://doi.org/10.1016/S0022-510X(01)00572-X.

    Article  CAS  PubMed  Google Scholar 

  6. A. Fambiatos, V. Jokubaitis, D. Horakova, et al., “Risk of secondary progressive multiple sclerosis: A longitudinal study,” Mult. Scler., 26, No. 1, 79–90 (2020), https://doi.org/10.1177/1352458519868990.

    Article  PubMed  Google Scholar 

  7. F. B. S. Briggs, J. C. Yu, M. F. Davis, et al., “Multiple sclerosis risk factors contribute to onset heterogeneity,” Mult. Scler. Relat. Disord., 28, 11–16 (2019), https://doi.org/10.1016/j.msard.2018.12.007.

    Article  PubMed  Google Scholar 

  8. A. N. Boiko, B. T. Mugutdinova, and T. M. Mugutdinov, “Prognostic significance of neuropsychological tests in patients with typical remitting multiple sclerosis,” Med. Alfavit, 2, No. 17(354) (2018), https://elibrary.ru/item.asp?id=36574676.

  9. K. Tilling, M. Lawton, N. Robertson, et al., “Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort,” Health Technol. Assess., 20, No. 81, 1–48 (2016), https://doi.org/10.3310/hta20810.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Proceedings of the Third All-Russian Congress with International Participation, “Multiple Sclerosis and Other Demyelinating Diseases (ROKIRS/RUCTRIMS Congress), Ekaterinburg, Sept. 13–16, 2018, Zh. Nevrol. Psikhiat., 118, No. 8, Spec. Iss., 128–171 (2018), https://doi.org/10.17116/jnevro2018118082128.

  11. A. I. Volkov and E. V. Popova, “New tools for early detection of the progression of multiple sclerosis,” Zh. Nevrol. Psikhiatr., 120, No. 7–2 (2020), https://doi.org/10.17116/jnevro202012007243.

  12. S. S. Jordy, A. Starzewski, Jr., F. A. Macedo, et al., “Olfactory alterations in patients with multiple sclerosis,” Arq. Neuropsiquiatr., 74, No. 9, 697–700 (2016), https://doi.org/10.1590/0004-282X20160128.

    Article  PubMed  Google Scholar 

  13. L. Tonetti, F. Camilli, S. Giovagnoli, et al., “Circadian activity rhythm in early relapsing-remitting multiple sclerosis,” J. Clin. Med., 8, No. 12 (2019), https://doi.org/10.3390/jcm8122216.

  14. O. Mirmosayyeb, S. Brand, M. Barzegar, et al., “Clinical characteristics and disability progression of early- and late-onset multiple sclerosis compared to adult-onset multiple sclerosis,” J. Clin. Med., 9, No. 5 (2020), https://doi.org/10.3390/jcm9051326.

  15. A. V. Genovese, J. Hagemeier, N. Bergsland, et al., “Atrophied brain T2 lesion volume at MRI is associated with disability progression and conversion to secondary progressive multiple sclerosis,” Radiology, 293, No. 2, 424–433 (2019), https://doi.org/10.1148/radiol.2019190306.

    Article  PubMed  Google Scholar 

  16. E. Fisher, J. C. Lee, K. Nakamura, and R. A. Rudick, “Gray matter atrophy in multiple sclerosis: a longitudinal study,” Ann. Neurol., 64, No. 3, 255–265 (2008), https://doi.org/10.1002/ana.21436.

    Article  PubMed  Google Scholar 

  17. L. K. Fisniku, P. A. Brex, D. R. Altmann, et al., “Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis,” Brain, 131, No. 3, 808–817 (2008), https://doi.org/10.1093/brain/awm329.

    Article  CAS  PubMed  Google Scholar 

  18. R. Cortese, S. Collorone, O. Ciccarelli, and A. T. Toosy, “Advances in brain imaging in multiple sclerosis,” Ther. Adv. Neurol. Disord., 12 (2019), https://doi.org/10.1177/1756286419859722.

  19. A. Eshaghi, R. V. Marinescu, A. L. Young, et al., “Progression of regional grey matter atrophy in multiple sclerosis,” Brain, 141, No. 6, 1665–1677 (2018), https://doi.org/10.1093/brain/awy088.

    Article  PubMed  PubMed Central  Google Scholar 

  20. A. Eshaghi, F. Prados, W. J. Brownlee, et al., and the MAGNIMS study group., “Deep gray matter volume loss drives disability worsening in multiple sclerosis,” Ann. Neurol., 83, No. 2, 210–222 (2018), https://doi.org/10.1002/ana.25145.

  21. M. Bross, M. Hackett, and E. Bernitsas, “Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis,” Int. J. Mol. Sci., 21, No. 12, 4312 (2020), https://doi.org/10.3390/ijms21124312.

    Article  CAS  PubMed Central  Google Scholar 

  22. A. Gajofatto, M. Calabrese, M. D. Benedetti, and S. Monaco, “Clinical, MRI, and CSF markers of disability progression in multiple sclerosis,” Dis. Markers, 35, 484959 (2013), https://doi.org/10.1155/2013/484959.

    Article  Google Scholar 

  23. B. Audoin, G. R. Davies, L. Finisku, et al., “Localization of grey matter atrophy in early RRMS,” J. Neurol., 253, No. 11, 1495–1501 (2006), https://doi.org/10.1007/s00415-006-0264-2.

    Article  PubMed  Google Scholar 

  24. M. A. Rocca, S. Mesaros, E. Pagani, et al., “Thalamic damage and long-term progression of disability in multiple sclerosis,” Radiology, 257, No. 2, 463–469 (2010), https://doi.org/10.1148/radiol.10100326.

    Article  PubMed  Google Scholar 

  25. P. Preziosa, M. A. Rocca, S. Mesaros, et al., “Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study,” Radiology, 260, No. 2, 541–550 (2011), https://doi.org/10.1148/radiol.11110315.

    Article  PubMed  Google Scholar 

  26. R. J. Fox, T. Cronin, J. Lin, et al., “Measuring myelin repair and axonal loss with diffusion tensor imaging,” AJNR Am. J. Neuroradiol., 32, No. 1, 85–91 (2011), https://doi.org/10.3174/ajnr.A2238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. R. T. Naismith, J. Xu, N. T. Tutlam, et al., “Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole,” Neurology, 74, No. 21, 1694–1701 (2010), https://doi.org/10.1212/WNL.0b013e3181e042c4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. D. Ontaneda and R. J. Fox, “Imaging as an outcome measure in multiple sclerosis,” Neurotherapeutics, 14, No. 1, 24–34 (2017), https://doi.org/10.1007/s13311-016-0479-6.

    Article  CAS  PubMed  Google Scholar 

  29. M. Absinta, P. Sati, and D. S. Reich, “Advanced MRI and staging of multiple sclerosis lesions,” Nat. Rev. Neurol., 12, No. 6, 358–368 (2016), https://doi.org/10.1038/nrneurol.2016.59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. A. Dal-Bianco, G. Grabner, C. Kronnerwetter, et al., “Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging,” Acta Neuropathol., 133, No. 1, 25–42 (2017), https://doi.org/10.1007/s00401-016-1636-z.

    Article  CAS  PubMed  Google Scholar 

  31. C. Elliott, J. S. Wolinsky, S. L. Hauser, et al., “Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions,” Mult. Scler., 25, No. 14, 1915–1925 (2019), https://doi.org/10.1177/1352458518814117.

    Article  PubMed  Google Scholar 

  32. A. A. Bogdan, Changes in the Functional State of Brain Matter in Multiple Sclerosis Based on Proton Magnetic Resonance Spectroscopy Data (2020), publ. online, https://cutt.ly/cjFwnIN, acc. Jan. 18, 2021.

  33. V. I. Golovkin, A. V. Pozdnyakov, Yu. F. Kamynin, and I. S. Martens, “New techniques for predicting therapy in multiple sclerosis,” Byull. Sib. Med., 9, No. 4, 138–144 (2010), https://doi.org/10.20538/1682-0363-2010-4-138-144.

  34. R. Srinivasan, N. Sailasuta, R. Hurd, et al., “Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T,” Brain, 128, No. 5, 1016–1025 (2005), https://doi.org/10.1093/brain/awh467.

    Article  PubMed  Google Scholar 

  35. T. A. Kobys’, “Neuroimaging predictors of the progression of disability in multiple sclerosis,” Vestn. Sovrem. Klin. Med., 9, No. 4 (2016), https://cyberleninka.ru/article/n/neyrovizualizatsionnye-prediktory-progressirovaniya-invalidizatsii-pri-rasseyannom-skleroze, acc. Dec. 3, 2020.

  36. C. Tur, A. Eshaghi, D. R. Altmann, et al., “Structural cortical network reorganization associated with early conversion to multiple sclerosis,” Sci. Rep., 8, No. 1, 10715 (2018), https://doi.org/10.1038/s41598-018-29017-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. T. Charalambous, C. Tur, F. Prados, et al., “Structural network disruption markers explain disability in multiple sclerosis,” J Neurol. Neurosurg. Psychiatry, 90, No. 2, 219–226 (2019), https://doi.org/10.1136/jnnp-2018-318440.

    Article  PubMed  Google Scholar 

  38. B. Nourbakhsh and E. M. Mowry, “Multiple sclerosis risk factors and pathogenesis,” Continuum (Minneap. Minn.), 25, No. 3, 596–610 (2019), https://doi.org/10.1212/CON.0000000000000725.

    Article  Google Scholar 

  39. C. E. Teunissen, H. Tumani, S. Engelborghs, and B. Mollenhauer, “Biobanking of CSF: international standardization to optimize biomarker development,” Clin. Biochem., 47, No. 4–5, 288–292 (2014), https://doi.org/10.1016/j.clinbiochem.2013.12.024.

    Article  PubMed  Google Scholar 

  40. M. Tintore, À. Rovira, J. Río, et al., “Defining, high, medium and low impact prognostic factors for developing multiple sclerosis,” Brain, 138, No. 7, 1863–1874 (2015), https://doi.org/10.1093/brain/awv105.

    Article  PubMed  Google Scholar 

  41. J. Kuhle, G. Disanto, R. Dobson, et al., “Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study,” Mult. Scler., 21, No. 8, 1013–1024 (2015), https://doi.org/10.1177/1352458514568827.

    Article  CAS  PubMed  Google Scholar 

  42. G. Hinsinger, N. Galéotti, N. Nabholz, et al., “Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis,” Mult. Scler., 21, No. 10, 1251–1261 (2015), https://doi.org/10.1177/1352458514561906.

    Article  CAS  PubMed  Google Scholar 

  43. M. S. Boesen, P. E. H. Jensen, M. Magyari, et al., “Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes,” Mult. Scler. Relat. Disord., 24, 175–183 (2018), https://doi.org/10.1016/j.msard.2018.05.017.

    Article  PubMed  Google Scholar 

  44. E. Thouvenot, G. Hinsinger, C. Demattei, et al., “Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome,” Mult. Scler., 25, No. 5, 669–677 (2019), https://doi.org/10.1177/1352458518767043.

    Article  CAS  PubMed  Google Scholar 

  45. P. Kušnierová, D. Zeman, P. Hradílek, et al., “Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases,” PLoS One, 15, No. 5, e0233519 (2020), https://doi.org/10.1371/journal.pone.0233519.

  46. S. Modvig, M. Degn, H. Roed, et al., “Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis,” Mult. Scler., 21, No. 14, 1761–1770 (2015), https://doi.org/10.1177/1352458515574148.

    Article  CAS  PubMed  Google Scholar 

  47. F. Baldacci, S. Lista, G. Palermo, et al., “The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development,” Expert Rev. Proteomics, 16, No. 7, 593–600 (2019), https://doi.org/10.1080/14789450.2019.1628643.

    Article  CAS  PubMed  Google Scholar 

  48. M. Khalil and J. Salzer, “CSF neurofilament light,” Neurology, 87, No. 11, 1068 (2016), https://doi.org/10.1212/WNL.0000000000003107.

  49. D. L. Dong, Z. S. Xu, M. R. Chevrier, et al., “Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M,” J. Biol. Chem., 268, No. 22, 16,679–16,687 (1993).

    Article  CAS  Google Scholar 

  50. M. Khalil, C. E. Teunissen, M. Otto, et al., “Neurofilaments as biomarkers in neurological disorders,” Nat. Rev. Neurol., 14, No. 10, 577–589 (2018), https://doi.org/10.1038/s41582-018-0058-z.

    Article  CAS  PubMed  Google Scholar 

  51. C. Barro, P. Benkert, G. Disanto, et al., “Serum neurofilament as a predictor of disease worsening and Brain and spinal cord atrophy in multiple sclerosis,” Brain, 141, No. 8, 2382–2391 (2018), https://doi.org/10.1093/brain/awy154.

    Article  PubMed  Google Scholar 

  52. O. Ciccarelli, “Multiple sclerosis in 2018: new therapies and biomarkers,” Lancet Neurol., 18, No. 1, 10–12 (2019), https://doi.org/10.1016/S1474-4422(18)30455-1.

    Article  PubMed  Google Scholar 

  53. J. Kuhle, G. Disanto, J. Lorscheider, et al., “Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis,” Neurology, 84, No. 16, 1639–1643 (2015), https://doi.org/10.1212/WNL.0000000000001491.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. L. Gaetani, F. Boscaro, G. Pieraccini, et al., “Host and microbial tryptophan metabolic profiling in multiple sclerosis,” Front. Immunol., 11 (2020), https://doi.org/10.3389/fimmu.2020.00157.

  55. C. K. Lim, A. Bilgin, D. B. Lovejoy, et al., “Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression,” Sci. Rep., 7, 41473 (2017), https://doi.org/10.1038/srep41473.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. P. Ak and B. Se, “The role of the gut microbiome in multiple sclerosis risk and progression: Towards characterization of the ‘MS microbiome’,” Neurotherapeutics, 15 (2018), https://doi.org/10.1007/s13311-017-0587-y.

  57. L. Dennison, M. Brown, S. Kirby, and I. Galea, “Do people with multiple sclerosis want to know their prognosis? A UK nationwide study,” PLoS One, 13, No. 2 (2018), https://doi.org/10.1371/journal.pone.0193407.

  58. R. Magliozzi, O. W. Howell, R. Nicholas, et al., “Inflammatory intrathecal profiles and cortical damage in multiple sclerosis,” Ann. Neurol., 83, No. 4, 739–755 (2018), https://doi.org/10.1002/ana.25197.

    Article  CAS  PubMed  Google Scholar 

  59. D. A. Häring, H. Kropshofer, L. Kappos, et al., “Long-term prognostic value of longitudinal measurements of blood neurofilament levels,” Neurol. Neuroimmunol. Neuroinflamm., 7, No. 5, e856 (2020), https://doi.org/10.1212/NXI.0000000000000856.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Challenges in Design, Analysis and Reporting of Prognostic and Predictive Marker Research – from Single Studies to an EBM Based Assessment, Accessed March 3, 2021, https://methods.cochrane.org/sites/methods.cochrane.org.prognosis/files/public/uploads/program+abstracts.pdf.

Download references

Author information

Authors and Affiliations

  1. Siberian State Medical University, Russian Ministry of Health, Tomsk, Russia

    V. M. Alifirova, E. M. Kamenskikh, E. S. Koroleva, E. V. Kolokolova & A. M. Petrakovich

Authors
  1. V. M. Alifirova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. M. Kamenskikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. S. Koroleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. V. Kolokolova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. M. Petrakovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. M. Kamenskikh.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 2, pp. 22–27, February, 2022.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alifirova, V.M., Kamenskikh, E.M., Koroleva, E.S. et al. Prognostic Markers in Multiple Sclerosis. Neurosci Behav Physi 52, 865–870 (2022). https://doi.org/10.1007/s11055-022-01310-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-022-01310-7

Keywords

Search

Navigation